The initial Phase 1 trial showed brilliant responses in 94 patients with naïve or relapsed/refractory CLL/SLL (ORR 96.2%), without differences based on high-risk genetic features (ORR 100% in del(17p) and TP53 mutation) [57]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.